SELECTED: Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Other)
Overall Status
Recruiting
CT.gov ID
NCT05911152
Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital (Other), Peking University First Hospital (Other)
2,000
1
108
18.5

Study Details

Study Description

Brief Summary

The goal of this observational study is to explore the safety and feasibility of laparoscopic intracorporeal anastomosis in colorectal cancer surgery. The main questions it aims to answer are: 1. If intracorporeal anastomosis is safe in terms of short-term outcome? 2. If intracorporeal anastomosis can achieve the same oncological outcome as conventional extracorporeal anastomosis?

Condition or Disease Intervention/Treatment Phase
  • Procedure: Intracorporeal anastomosis

Detailed Description

This study is a retrospective real-world research initiated by the Chinese Academy of Medical Sciences Cancer Hospital, including Cancer Hospital of the Chinese Academy of Medical Sciences, Shenzhen Hospital and Peking University First Hospital. The study aims to retrospectively analyze the clinical data of approximately 2,000 patients who underwent laparoscopic surgery with preoperative imaging staging of cT1-4aNanyM0 and pathological diagnosis of adenocarcinoma or high-grade intraepithelial neoplasia from April 2016 to April 2020. The patients will be divided into the intracorporeal anastomosis group (IA) and extracorporeal anastomosis group (EA) based on the surgical records. The primary endpoints of the study are 3-year disease-free survival (DFS) and 3-year overall survival (OS). The secondary endpoints include overall complication rate within 30 days, postoperative pain score, time to first flatus after surgery, time to first bowel movement after surgery, time to first oral intake after surgery, length of hospital stay, and postoperative quality of life.

Study Design

Study Type:
Observational
Anticipated Enrollment :
2000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study
Actual Study Start Date :
Jan 1, 2016
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Intracorporeal anastomosis

Patients underwent laparoscopic colorectal surgery with intracorporeal anastomosis

Procedure: Intracorporeal anastomosis
Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection

Extracorporeal anastomosis

Patients underwent laparoscopic colorectal surgery with extracorporeal anastomosis

Outcome Measures

Primary Outcome Measures

  1. 3-year disease free survival [3 year]

    Proportion of patients who remain alive without any signs or symptoms of disease recurrence or progression for a period of 3 years after surgery

  2. 3-year overall survival [3 year]

    Percentage of patients who are still alive at the end of a 3-year period after surgery

Secondary Outcome Measures

  1. Rate of postoperative complications [30 days]

    Rate of postoperative complications within 30 days after surgery

  2. Time to first flatus after surgery [7 days]

    Time to first flatus after surgery

  3. Time to first stool after surgery [7 days]

    Time to first stool after surgery

  4. Length of stay after surgery [30 days]

    Length of stay after surgery

  5. Postoperative pain score [3 days]

    VAS (Visual Analog Scale) score is used to assess the postoperative pain level in patients. It is a measurement tool used to assess the intensity or severity of a subjective experience, typically related to pain or discomfort. The VAS score involves a straight line or a numerical scale ranging from 0 to 10, where 0 represents no pain or discomfort and 10 represents the worst possible pain or discomfort. Individuals are asked to indicate their level of pain or discomfort by marking a point on the scale, and the score is determined by measuring the distance from the 0 mark to the marked point. The VAS score provides a subjective assessment of pain or discomfort experienced by an individual.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients voluntarily enrolled in this study and signed an informed consent form;

  2. Age: 18-75 years;

  3. Completion of colonoscopy and biopsy, with pathological confirmation of adenocarcinoma or high-grade intraepithelial neoplasia;

  4. Preoperative enhanced CT or MRI examination showing no evidence of distant metastasis;

  5. Preoperative staging as cT1-3NanyM0;

  6. Underwent laparoscopic surgery.

Exclusion Criteria:
  1. Contraindications to laparoscopic surgery;

  2. Cases requiring emergency surgery due to acute bowel obstruction, perforation, or bleeding;

  3. Patients with distant metastasis;

  4. Patients with multiple primary colorectal cancers;

  5. Patients with a history of malignancy;

  6. Patients unwilling to sign the informed consent or unwilling to follow the study protocol for follow-up.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cancer Hospital Chinese Academy of Medical Sciences Beijing Beijing China 100021

Sponsors and Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital
  • Peking University First Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jianqiang Tang, Associate professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier:
NCT05911152
Other Study ID Numbers:
  • NCC4050
First Posted:
Jun 20, 2023
Last Update Posted:
Jun 27, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jianqiang Tang, Associate professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 27, 2023